- Home
- MDCX
as 11-18-2025 3:42pm EST
Stocks
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | W. CONSHOHOCKEN |
| Market Cap: | 50.8M | IPO Year: | N/A |
| Target Price: | $23.50 | AVG Volume (30 days): | 294.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.79 - $8.94 | Next Earning Date: | 11-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Medicus Pharma Ltd. Common Stock News
MDCX Breaking Stock News: Dive into MDCX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Medicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
ACCESS Newswire
4 days ago
Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights
ACCESS Newswire
6 days ago
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
ACCESS Newswire
21 days ago
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome
GlobeNewswire
21 days ago
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome
ACCESS Newswire
a month ago
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
ACCESS Newswire
a month ago
Three Biotech Companies Redefining Value Creation Through Dual Strategies
ACCESS Newswire
a month ago
The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets
Compare MDCX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDCX Medicus Pharma Ltd. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.